AptarGroup 배당 및 자사주 매입
배당 기준 점검 5/6
AptarGroup 수익으로 충분히 충당되는 현재 수익률 1.57% 보유한 배당금 지급 회사입니다. 다음 지급일은 27th May, 2026 이며 배당락일은 다음과 같습니다. 6th May, 2026.
핵심 정보
1.6%
배당 수익률
4.5%
자사주 매입 수익률
| 총 주주 수익률 | 6.1% |
| 미래 배당 수익률 | 1.8% |
| 배당 성장률 | 4.3% |
| 다음 배당 지급일 | 27 May 26 |
| 배당락일 | 06 May 26 |
| 주당 배당금 | n/a |
| 배당 성향 | 31% |
최근 배당 및 자사주 매입 업데이트
Recent updates
분석 기사 • May 03
Analyst Estimates: Here's What Brokers Think Of AptarGroup, Inc. (NYSE:ATR) After Its First-Quarter Report
Shareholders might have noticed that AptarGroup, Inc. ( NYSE:ATR ) filed its first-quarter result this time last week...
내러티브 업데이트 • Apr 28
ATR: Nasal Therapies And Share Buybacks Will Support Future Upside
Analysts have kept their $144.00 price target on AptarGroup unchanged, citing relatively steady assumptions around discount rate, revenue growth, profit margin, and future P/E. These factors support the view that the stock’s current valuation framework still holds.내러티브 업데이트 • Apr 14
ATR: Nasal Drug Delivery Pipeline And Leadership Transition Will Shape Future Upside
Analysts have reaffirmed AptarGroup's price target at $144.00, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E that together suggest a steady view of the company’s valuation. What's in the News AptarGroup’s Unidose Powder Nasal Spray System is being used in ENA Respiratory’s Phase II study of INNA-051, an investigational once-weekly nasal spray aimed at helping protect adults at higher risk from symptomatic viral respiratory infections (Key Developments).내러티브 업데이트 • Mar 30
ATR: Nasal And Eye Care Drug Delivery Will Drive Future Upside
Analysts have raised their price target on AptarGroup from $133 to $144. This reflects updated views on its fair value based on revised assumptions for discount rate, revenue growth, profit margin, and future P/E.
내러티브 업데이트 • Mar 16
ATR: Share Repurchases Will Support Upside Potential In Drug Delivery Portfolio
Analysts have modestly revised their price target on AptarGroup, keeping fair value steady at about $212.79 while fine tuning assumptions on discount rate, revenue growth, profit margin and future P/E. This reflects updated views on the company’s risk profile and earnings potential.내러티브 업데이트 • Mar 02
ATR: Share Repurchases And Nasal Drug Delivery Portfolio Will Support Upside Potential
Analysts have trimmed their price target on AptarGroup slightly to about $213, reflecting updated assumptions around a modestly higher discount rate, a small change in estimated fair value and adjusted expectations for revenue growth, profit margins and future P/E levels. What's in the News AptarGroup issued earnings guidance for the first quarter of 2026, with earnings per share framed using a 1.18 EUR to US$ exchange rate assumption.
내러티브 업데이트 • Feb 16
ATR: Drug Delivery Platforms And Buybacks Will Support Attractive Future Returns
Analysts have raised their price target for AptarGroup to $161.43 from $159.14, reflecting updated views on the company’s discount rate, revenue growth assumptions, profit margin outlook, and future P/E expectations. What's in the News AptarGroup issued earnings guidance for the first quarter of 2026, with earnings per share framed using a 1.18 EUR to US$ exchange rate assumption.내러티브 업데이트 • Feb 02
ATR: Nasal And Eye Care Drug Delivery Platforms Will Support Balanced Outlook
AptarGroup's analyst price target has changed from US$153 to US$133 as analysts incorporate updated assumptions for the discount rate, revenue growth, profit margin, and future P/E. What's in the News AptarGroup's LuerVax and Spray Divider nasal delivery systems are being used in CastleVax's Phase II clinical trial of CVAX-01, an intranasal COVID-19 vaccine candidate that is being assessed against an FDA approved injectable mRNA vaccine in around 200 U.S. adults, including higher risk and older participants (Key Developments).내러티브 업데이트 • Jan 19
ATR: Nasal And Eye Drug Delivery Platforms Will Support Attractive Future Returns
Analysts have trimmed their price target on AptarGroup to about $159 from roughly $161, reflecting slightly adjusted assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E that remain broadly consistent with prior views. What's in the News AptarGroup’s nasal vaccine delivery systems, LuerVax and Spray Divider, are being used in CastleVax’s Phase II clinical trial of CVAX-01, an intranasal COVID-19 vaccine candidate assessing safety, tolerability and immune response versus an FDA approved injectable mRNA vaccine in about 200 U.S. adults, including higher risk and older participants (Key Developments).내러티브 업데이트 • Jan 05
ATR: Pharma Nasal Delivery Momentum Will Drive Attractive Long Term Returns
Narrative Update on AptarGroup Analyst Price Target Analysts have modestly raised their price target for AptarGroup to approximately 161.43 dollars, reflecting slightly higher long term return expectations and a marginally richer future earnings multiple. What's in the News Aptar's Bidose liquid nasal spray system has been selected to deliver the newly FDA approved CARDAMYST nasal spray for acute PSVT episodes in adults, which underscores Aptar's role in emergency cardiovascular therapies (FDA announcement) The company completed a 1.50 million share repurchase, about 2.27 percent of shares outstanding, for approximately 227.34 million dollars under its October 2024 buyback program, which signals continued capital return to shareholders (company disclosure) Nasus Pharma extended and updated its long running collaboration with Aptar through a new master services agreement that covers development, analytical, regulatory, and consulting support for its intranasal epinephrine program using Aptar's unit dose powder nasal delivery system (Nasus Pharma announcement) A new supply agreement makes Aptar France the exclusive provider of UDSp devices to Nasus Pharma for its intranasal epinephrine products, with milestone payments and royalties tied to NDA submission, approval, and commercial sales (Nasus Pharma announcement) Valuation Changes Fair value estimate: unchanged at approximately 161.43 dollars per share, indicating no revision to the intrinsic value assessment.분석 기사 • Jan 02
We Like These Underlying Return On Capital Trends At AptarGroup (NYSE:ATR)
To find a multi-bagger stock, what are the underlying trends we should look for in a business? In a perfect world, we'd...내러티브 업데이트 • Dec 15
ATR: Share Repurchases And Nasal Drug Delivery Partnership Will Support Upside Potential
Narrative Update Analysts have modestly reduced their price target on AptarGroup, trimming fair value expectations from approximately $220.00 to about $213.03. They cite updated assumptions for slower revenue growth, slightly lower profit margins, and a higher future price to earnings multiple within their discounted cash flow framework.내러티브 업데이트 • Nov 30
ATR: Share Buyback and Expanded Pharma Partnerships Will Drive Future Upside
Analysts have slightly raised their price target for AptarGroup to $161.43, citing a modest increase in expected profit margins as well as an updated outlook on revenue growth and future price-to-earnings ratios. What's in the News Between July and September 2025, AptarGroup completed the repurchase of over 1.5 million shares for approximately $227.34 million as part of its ongoing buyback program (Company Filing).내러티브 업데이트 • Nov 16
ATR: Share Buyback and Pharma Supply Moves Will Unlock Upside
Narrative Update on AptarGroup Price Target Analysts have revised AptarGroup’s fair value estimate downward by approximately $9 to $161.43 per share, citing tempered growth projections and a modest increase in the discount rate as key factors behind the adjustment. What's in the News Completed share repurchases totaling 1,504,552 shares for $227.34 million under the buyback announced on October 10, 2024 (Buyback Tranche Update).Seeking Alpha • Nov 02
AptarGroup: Pharma Setback Creates Long-Term Opportunities
Summary AptarGroup's shares have dropped over 25% from summer highs due to slower growth, especially in high-margin pharma emergency solutions. ATR's valuation has compressed from 26x to 20x earnings, reflecting concerns about flat growth and a soft outlook for 2026. Pharma remains the most profitable segment, but headwinds in emergency-use delivery systems are expected to impact revenues next year. While the stock is approaching attractive valuation territory, risks remain for earnings growth in 2026, making the opportunity reasonable but not extremely compelling yet. Read the full article on Seeking Alpha내러티브 업데이트 • Nov 01
ATR: Expanded Partnership Agreements Will Drive Long-Term Healthcare Solutions
Analysts have revised their price target for AptarGroup downward from $177 to $170.71. They cited modest changes in discount rate expectations, a slight increase in projected revenue growth, and softer projected profit margins and future valuation multiples.분석 기사 • Oct 18
AptarGroup (NYSE:ATR) Is Increasing Its Dividend To $0.48
The board of AptarGroup, Inc. ( NYSE:ATR ) has announced that it will be increasing its dividend by 6.7% on the 13th of...내러티브 업데이트 • Sep 05
Advanced Drug Delivery And Sustainable Packaging Will Transform Global Healthcare
The uptick in AptarGroup’s consensus price target to $178.43 is primarily driven by a modest increase in its forward P/E multiple, while revenue growth expectations remain stable. What's in the News Held Analyst/Investor Day.분석 기사 • Aug 28
AptarGroup, Inc.'s (NYSE:ATR) Business Is Trailing The Market But Its Shares Aren't
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 19x, you may...분석 기사 • Jul 15
AptarGroup's (NYSE:ATR) Dividend Will Be $0.45
AptarGroup, Inc. ( NYSE:ATR ) will pay a dividend of $0.45 on the 14th of August. The dividend yield is 1.1% based on...분석 기사 • Jul 02
Are Investors Undervaluing AptarGroup, Inc. (NYSE:ATR) By 28%?
Key Insights AptarGroup's estimated fair value is US$220 based on 2 Stage Free Cash Flow to Equity Current share price...분석 기사 • Jun 19
These 4 Measures Indicate That AptarGroup (NYSE:ATR) Is Using Debt Reasonably Well
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...분석 기사 • May 13
AptarGroup's (NYSE:ATR) Returns Have Hit A Wall
If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...Seeking Alpha • Dec 02
AptarGroup Has Gotten Too Expensive
Summary AptarGroup specializes in niche packaging solutions for pharmaceuticals, beauty, food, and personal care, with impressive growth and a strong market presence. Despite recent stock performance, I find AptarGroup shares expensive, leading me to downgrade from 'hold' to a 'soft sell' rating. The company's financials show revenue and profitability growth, but valuation metrics indicate shares are overvalued compared to peers. AptarGroup's robust balance sheet and share buyback program are positives, but high trading multiples warrant a more cautious investment stance. Read the full article on Seeking Alpha
새 내러티브 • Aug 25
Proprietary Drug Delivery And Digital Health Innovations To Spearhead Revenue Surge
Expansion in digital health services and sustainability initiatives may enhance brand value and open up new market opportunities, driving future growth.지급의 안정성과 성장
배당 데이터 가져오는 중
안정적인 배당: ATR 의 주당 배당금은 지난 10 년 동안 안정적이었습니다.
배당금 증가: ATR 의 배당금 지급은 지난 10 년 동안 증가했습니다.
배당 수익률 vs 시장
| AptarGroup 배당 수익률 vs 시장 |
|---|
| 구분 | 배당 수익률 |
|---|---|
| 회사 (ATR) | 1.6% |
| 시장 하위 25% (US) | 1.4% |
| 시장 상위 25% (US) | 4.2% |
| 업계 평균 (Packaging) | 3.4% |
| 분석가 예측 (ATR) (최대 3년) | 1.8% |
주목할만한 배당금: ATR 의 배당금( 1.57% )은 US 시장에서 배당금 지급자의 하위 25%( 1.39% )보다 높습니다.
고배당: ATR 의 배당금( 1.57% )은 US 시장에서 배당금 지급자의 상위 25%( 4.21% )와 비교해 낮습니다.
주주 대상 이익 배당
수익 보장: 합리적으로 낮은 지불 비율 ( 31.4% )로 ATR 의 배당금 지급은 수익으로 충분히 충당됩니다.
주주 현금 배당
현금 흐름 범위: 합리적으로 낮은 현금 지급 비율 ( 37.8% )로 ATR 의 배당금 지급은 현금 흐름으로 잘 충당됩니다.
높은 배당을 제공하는 우량 기업 찾기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/06 09:45 |
| 종가 | 2026/05/06 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
AptarGroup, Inc.는 16명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Ghansham Panjabi | Baird |
| Mark Wilde | BMO Capital Markets Equity Research |
| George Staphos | BofA Global Research |